Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decitabine (SuperGen).

A Manoharan1

  • 1Department of Clinical Haematology, St George Hospital, University of New South Wales, Sydney, Australia. manoharana@sesahs.nsw.gov.au

Idrugs : the Investigational Drugs Journal
|July 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knowledge, practices, and diagnostic barriers in chronic cough management among primary care doctors in Klang Valley, Malaysia: a cross-sectional survey.

BMC pulmonary medicine·2025
Same author

Central nervous system involvement in childhood acute lymphoblastic leukemia is linked to upregulation of cholesterol biosynthetic pathways.

Leukemia·2022
Same author

Proximal Fibular Osteochondroma Producing Common Peroneal Nerve Palsy in a Post-Cesarean Section Patient.

Oman medical journal·2019
Same author

A case report of an angiomyxoma in the liver.

Annals of the Royal College of Surgeons of England·2018
Same author

Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD.

QJM : monthly journal of the Association of Physicians·2017
Same author

Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2017
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Decitabine shows promise in treating myelodysplastic syndrome and leukemia, with high response rates and minimal side effects in clinical trials. Further studies are planned for sickle cell anemia.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Decitabine is a DNA methyltransferase inhibitor investigated for various hematological malignancies.
  • Previous studies indicated potential activity in myelodysplasia, leukemia, and post-transplant relapse.

Purpose of the Study:

  • To evaluate the efficacy and safety of decitabine in treating myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), and sickle cell anemia.
  • To assess response rates, duration, survival, and side effects in patients receiving decitabine therapy.

Main Methods:

  • Phase II and Phase I/II clinical trials were conducted.
  • Patients with MDS, CML, and sickle cell anemia received decitabine treatment.
  • Efficacy was measured by response rates, duration, and survival; safety was assessed by side effects.

Related Experiment Videos

Main Results:

  • Decitabine demonstrated a 49% response rate in 125 MDS patients and 48% in 66 evaluable MDS patients (median response duration 40 weeks, mean survival 13 months).
  • In CML patients, response rates were 62% in chronic phase, 52% in accelerated phase, and 25% in blastic phase.
  • In sickle cell anemia, 100% of 8 patients responded with elevated fetal hemoglobin, minimal side effects, and good tolerability.

Conclusions:

  • Decitabine is active in treating myelodysplastic syndrome and chronic myelogenous leukemia with acceptable safety profiles.
  • Decitabine shows significant potential for treating sickle cell anemia, warranting further investigation.
  • The drug's mechanism may involve reactivation of growth suppressor genes, impacting tumor cell lines.